Navigation Links
Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50

SAN FRANCISCO, April 20, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) ("the Company")and maintains its twelve month target price of $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "According to the Company, Opexa's lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is scheduled to advance into a pivotal Phase 3 clinical study in the U.S. in the second of half of 2011." Mr. Silver continued, "In clinical trials performed to date, Tovaxin® has compared favorably to already approved MS therapies, which are multi-billion dollar drugs. Of most significance in our opinion is Tovaxin® ranking ahead of both Copaxone® and Avonex® in Annualized Relapse Rate ("ARR"). ARR is possibly the most clinically relevant endpoint and is the single most important measure by which the FDA evaluates MS drugs for approval." Mr. Silver concluded, "Dendreon's Provenge®, the first FDA-approved autologous cellular immunotherapy which was recently approved by The Centers for Medicare and Medicaid Services for reimbursement of $93,000, has increased awareness and acceptance for this therapeutic approach."

To download a FREE copy of the Opexa Therapeutics, Inc. research report, please visit and complete the research form to gain access to the report.

About Vista Partners:

Vista Partners LLC, founded in 2005,  is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit the Vista Partners website at or click here.

877.215.4813 or

SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
2. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
3. Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairss VistA Imaging System
4. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
5. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
6. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
7. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
8. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
9. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
10. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
11. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
Post Your Comments:
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/25/2015)... Nov. 25, 2015 ... of the "Global Brain Monitoring Devices ... --> ) has announced ... Monitoring Devices Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, ... ... online platform for mental health and wellness consultation, has collaborated with Women’s ... holistically address their reader’s queries on topics on mental and emotional well-being ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer Brady, ... of Connecticut on behalf of a home health care worker who provided companionship services ... home health care workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... training center for the Narconon network, announced the release of a new cutting edge ... the Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... double board certified facial plastic surgeon specializing in both surgical and non-surgical treatments, ... The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained and ...
Breaking Medicine News(10 mins):